Pfizer to Receive 2.66 Billion Pounds From Haleon
Pfizer to Receive 2.66 Billion Pounds From Haleon in Share Deal
Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical company sold 640 million ordinary shares in British consumer-healthcare business Haleon at 380 pence a share.
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon
Pfizer has sold a stake in British consumer healthcare group Haleon worth about $3.26 billion, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.
Drug giant Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon
Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.
Pfizer to offload about 6% stake in Sensodyne-maker Haleon, says bookrunner
Haleon separately said on Monday it had agreed to make an off-market purchase of about 230 million pounds ($308.18 million) worth of ordinary shares from Pfizer. In March, the U.S. pharma major had sold about $3.
Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
Medscape1d
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
Unique program from IC Stars, sponsored by Pfizer, helps moms start careers in tech
I.C. Stars has started a new, unique program in partnership with a nonprofit to help new mothers start careers in information ...
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
bovnews16h
Pfizer Inc (PFE) Stock Dilemma: A Surge That Has Everyone Talking—What’s the Real Story?
On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.09 which represents a slight increase of $0.12 or 0.41% from the prior close of $28.97. The stock opened at $29.02 and ...
STAT4d
What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...